PsABIOnd Study and eDaily Substudy Design: Long-Term Effectiveness and Safety of Guselkumab and IL-17 Inhibitors in Routine Clinical Practice in Patients with Psoriatic Arthritis

PsABIOnd Study and eDaily Substudy Design: Long-Term Effectiveness and Safety of Guselkumab and IL-17 Inhibitors in Routine Clinical Practice in Patients with Psoriatic Arthritis

Plain Language Summary Psoriatic arthritis (PsA) is a type of arthritis associated with inflammation that occurs in almost one-third of patients with the inflammatory skin condition psoriasis. PsA can vary between individuals, and typically causes joint pain, swelling and stiffness, affecting both p...

Full description

Bibliographic Details
Main Authors: Stefan Siebert, Frank Behrens, Ennio Lubrano, Nicolas Martin, Mohamed Sharaf, Christine Contré, Elke Theander, Rubén Queiro, Miriam Zimmermann, Laure Gossec
Format: Article
Language:English
Published: Adis, Springer Healthcare 2022-12-01
Series:Rheumatology and Therapy
Subjects:
Psoriatic arthritis
Real-world evidence
Guselkumab
Biological disease-modifying anti-rheumatic drugs (bDMARDs)
IL-17 inhibitors
eHealth
Online Access:https://doi.org/10.1007/s40744-022-00518-w

Internet

https://doi.org/10.1007/s40744-022-00518-w

Similar Items